Hyderabad is more or less the pharma capital of India, and there are many firms that have off-shore activities and collaborate with foreign companies. Sai Life Sciences is a leading global contract, research, development, and manufacturing organization (CRO-CDMO) that has opened a new biology facility at its integrated R&D campus in Hyderabad, India.
The company intends to position itself as a leading player in Discovery Biology. According to its managing director Krishna Kanumuri, the new facility marks the completion of a two-year journey of creating differentiated value for our discovery clients through an integrated delivery model across Boston and Hyderabad. The company feels it will add value by bringing together the best talent, technology, complementary services, and efficiency at scale.
The new facility has extended in vitro and in vivo biology services, DMPK, toxicology, and a vivarium. The facility will combine capabilities and capacity for accelerating integrated drug discovery programs. In 2019, it opened its R&D facility in Boston, USA. It was designed to offer start-up and biotech companies in the region biological services to address exploratory and custom biology needs.
The company’s discovery services support global innovator companies from start-ups to large pharma companies across diverse areas, including oncology, CNS, antivirals, and inflammation, among others.
The latest facility will unify the discovery, early and late phase development, and clinical supply capabilities in a single 13-acre campus, which has around 1000 scientists delivering integrated value at scale.